ABT

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Yahoo · 1d ago

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

Yahoo · 3d ago

The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.

Yahoo · 3d ago

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

Yahoo · 3d ago

SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the "SRC")

Yahoo · 4d ago

Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

Yahoo · 4d ago

MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

Yahoo · 4d ago